Biotechlineup
Oct 28, 4:18 PM
$NVAX $MRNA $BCTX $SMMT $MRK Moderna’s cancer vaccine " has not met expectations " and will fail commercially. Bria Cell utilizes OFF shelf cellular matching, Breast cancer vaccine near approval. Has a melanoma vaccine that addresses the same patient population as Moderna’s personalized neoantigen vaccine. A little needle pinch minimal side effects and better outcome. Novavax will utilize Matrix M in Off shelf cancer vaccines Old adjuvants only trigger antibodies, Matrix M induces robust MHC-1 and MHC-ll cross-presentation. This means it can take pre manufactured tumor protein fragments (Off shelf tumor antigens) and train killer CD8+ T-cells to hunt down a tumor instantly upon injection, completely bypassing the need to sequence individual patient biopsies. Summits ivonescimab with a PDF1/ anti vegt mechanism is the future bispecific, cancer vaccines formulated with Matrix M are designed to act as the ideal combination partner.
0 replies
